ZBIO · Zenas BioPharma, Inc.

Summary

Zenas BioPharma reported financial results for the quarter and year ended December 31, 2025, with net loss of $240.4 million and $377.7 million, respectively, cash and equivalents of $360.5 million, and secured up to $250 million non-dilutive debt financing from Pharmakon. The company announced plans for obexelimab BLA submission to FDA in Q2 2026 following positive Phase 3 INDIGO results.

Key takeaways

• Event Type: Fourth Quarter and Full Year 2025 Financial Results and Corporate Update (Items: 2.02, 2.03)